Keyphrases
Cardiac Myosin
100%
Systolic Heart Failure
100%
Myosin Activation
100%
Omecamtiv Mecarbil
100%
Confidence Interval
33%
Placebo
33%
Hazard Ratio
33%
Placebo Groups
33%
Patients with Heart Failure
33%
Change from Baseline
33%
Heart Failure Events
33%
No Significant Difference
16%
Cardiac Function
16%
Hospitalization
16%
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
16%
Between-group
16%
Pharmacokinetics
16%
Low Incidence
16%
Ejection Fraction
16%
Heart Failure
16%
Heart Failure Death
16%
Twice Daily
16%
Chronic Heart Failure
16%
Ejection
16%
Total Symptom Score
16%
Ventricular Arrhythmia
16%
Cardiovascular Outcomes
16%
Cardiac Troponin
16%
Heart Failure Therapy
16%
Heart Failure with Preserved Ejection Fraction (HFpEF)
16%
Kansas City Cardiomyopathy Questionnaire
16%
Amgen
16%
EudraCT
16%
Ischemic Arrhythmia
16%
Cardiac Myosin Activator
16%
Medicine and Dentistry
Cardiac Myosin
100%
Heart Failure
100%
Systolic Heart Failure
100%
Omecamtiv Mecarbil
100%
Cardiovascular System
57%
Placebo
57%
Hazard Ratio
28%
Ejection Fraction
28%
Heart Function
14%
Brain Natriuretic Peptide
14%
Amino Terminal Sequence
14%
Cardiac Troponin
14%
Symptom
14%
Outpatient
14%
Heart Death
14%
Heart Ventricle Arrhythmia
14%
Cardiomyopathy
14%
Pharmacokinetics
14%
Troponin I
14%
Pharmacology, Toxicology and Pharmaceutical Science
Heart Failure
100%
Cardiac Myosin
100%
Systolic Heart Failure
100%
Omecamtiv Mecarbil
100%
Placebo
57%
Symptom
14%
Brain Natriuretic Peptide
14%
Pharmacokinetics
14%
Heart Death
14%
Cardiomyopathy
14%
Heart Ventricle Arrhythmia
14%
Troponin I
14%
Biochemistry, Genetics and Molecular Biology
Heart Ejection Fraction
100%
Cardiac Dysrhythmia
50%
Pharmacokinetics
50%
N-Terminus
50%
Heart Function
50%
Natriuretic Peptide
50%
Troponin I
50%
Cardiac Troponin
50%